Wednesday Jul 9
Threshold Announces Initiation Of Dosing With TH-302/Bortezomib In...
Threshold Pharmaceuticals, Inc. today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.
Threshold Pharmaceuticals Coverage Initiated by Analysts at Brean Capital
The firm set a "buy" rating and a $15.00 price target on the stock. Brean Capital's price target would indicate a potential upside of 265.85% from the stock's previous close.
Threshold Initiates Phase 2 Clinical Trial In Advanced Non-Squamous Non-Small Cell Lung Cancer
Threshold initiated a Phase 2 trial with TH-302 for the treatment of advanced non-squamous non-small cell lung carcinoma .
Threshold Pharmaceuticals Initiates 440-Patient, Randomized,...
The international Phase 2 trial is designed to compare the combination of TH-302 and pemetrexed versus the combination of pemetrexed and placebo as second-line therapy in this patient population.
Chemical & Engineering News
Biotech Future Looking Rosy
High above the flight deck of the U.S.S. Midway, aboard which the Biotechnology Industry Organization hosted a welcome party for its annual convention in San Diego last Monday, "Rosie" was written large in red lights.